Fulcrum Therapeutics
May 08, 2020
Overcoming the prevailing unmet needs in Beta-Thalassemia Market
The current Beta-thalassemia market is experiencing the emergence of gene therapies as a one-time cure for the patients. Beta thalassemia is relatively a common heterogeneous autosomal recessive hereditary blood disorder. It is a common form of hemoglobinopathy characterized by ineffective erythropoiesis leadi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
